Cancer stem cell and stromal microenvironment

Ochsner Journal

Volumn 13, Issue 1, 2013, Pages 109-118

  Li, Li ^a   Cole, John ^a   Margolin, David A ^a,b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cancer metastasis; Cancer stem cells; Drug resistance; Stromal cells; Tumor microenvironment

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1;

ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL CONTACT; CELL INTERACTION; COLORECTAL CANCER; FOLLICULAR LYMPHOMA; HUMAN; LYMPH NODE; LYMPHOMA; METASTASIS; NONHUMAN; OVARY CANCER; PROGNOSIS; PROSTATE CANCER; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84875130110     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (103)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012 Jul-Aug; 62(4):220-241. Epub 2012 Jun 14. Erratum in: CA Cancer J Clin. 2012 Sep-Oct;62(5):348.
2. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells. 2012 Mar;30(3):363-371.
3. Anderson EC, Hessman C, Levin TG, Monroe MM, Wong MH. The role of colorectal cancer stem cells in metastatic disease and therapeutic response. Cancers (Basel). 2011 Jan 1;3(1): 319-339.
4. National Cancer Institute. SEER Stat Fact Sheets: Colon and Rectum. 2012. http://seer.cancer.gov/statfacts/html/colorect. html. Accessed September 18, 2012.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. Epub 2012 Jan 4.
6. Gerger A, Zhang W, Yang D, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 1;17(21):6934-6943. Epub 2011 Sep 14.
7. Merlos-Suárez A, Barriga FM, Jung P, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell. 2011 May 6;8(5):511-524. Epub 2011 Mar 17.
8. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009 Sep;9(9):665-674. Epub 2009 Aug 20.
9. Grange C, Tapparo M, Collino F, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011 Aug 1; 71(15):5346-5356. Epub 2011 Jun 13.
10. Todaro M, Francipane MG, Medema JP, Stassi G. Colon cancer stem cells: promise of targeted therapy. Gastroenterology. 2010 Jun;138(6):2151-2162.
11. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267-284.
12. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008 Oct;8(10):755-768. Epub 2008 Sep 11.
13. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011 Mar;17(3):313-319.
14. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001 Nov 1;414(6859):105-111.
15. Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. 2011;2011; pii 396076. Epub 2010 Sep 29.
16. Overdevest JB, Thomas S, Kristiansen G, et al. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res. 2011 Jun 1; 71(11):3802-3811. Epub 2011 Apr 11.
17. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007 Jan 4;445(7123):106-110. Epub 2006 Nov 19.
18. Haraguchi N, Ohkuma M, Sakashita H, et al. CD133{thorn}CD44{thorn} population efficiently enriches colon cancer initiating cells. Ann Surg Oncol. 2008 Oct;15(10):2927-2933. Epub 2008 Jul 29.
19. Carpentino JE, Hynes MJ, Appelman HD, et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009 Oct 15;69(20):8208-8215. Epub 2009 Oct 6.
20. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-10163. Epub 2007 Jun 4.
21. Li CY, Li BX, Liang Y, et al. Higher percentage of CD133{thorn}cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Transl Med. 2009 Jul 7;7:56.
22. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133{thorn} and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest. 2008 Jun;118(6):2111-2120.
23. Horst D, Scheel SK, Liebmann S, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 2009 Dec;219(4):427-434.
24. Kim HS, Zhang X, Choi YS. Activation and proliferation of follicular dendritic cell-like cells by activated T lymphocytes. J Immunol. 1994 Oct 1;153(7):2951-2961.
25. Kim HS, Zhang X, Klyushnenkova E, Choi YS. Stimulation of germinal center B lymphocyte proliferation by an FDC-like cell line, HK. J Immunol. 1995 Aug 1;155(3):1101-1109.
26. Margolin DA, Silinsky J, Grimes C, et al. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1a/CXCR4 paracrine signaling. Neoplasia. 2011 Sep;13(9):874-886.
27. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998 Aug;16(8):2780-2795.
28. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 Nov 15;108(10):3295-3301. Epub 2006 Jul 27.
29. Das B, Tsuchida R, Malkin D, et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells. 2008 Jul;26(7):1818-1830. Epub 2008 May 8.
30. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007 May 15;67(10):4827-4833.
31. Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood. 2009 Jun 4; 113(23):5920-5926. Epub 2009 Feb 2.
32. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett. 2008 Sep 8;268(1):1-9. Epub 2008 May 19.
33. Zhang P, Zhang Y, Mao L, Zhang Z, Chen W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett. 2009 May 18;277(2):227-234. Epub 2009 Jan 30.
34. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-4419. Epub 2011 Feb 14.
35. Kruger JA, Kaplan CD, Luo Y, et al. Characterization of stem celllike cancer cells in immune-competent mice. Blood. 2006 Dec 1;108(12):3906-3912. Epub 2006 Aug 15.
36. Lee CG, Das B, Lin TL, et al. A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potential. Br J Haematol. 2012 Jul;158(1):79-90. Epub 2012 Apr 18.
37. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-14021. Epub 2009 Aug 4.
38. Annabi B, Rojas-Sutterlin S, Laflamme C, et al. Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol Cancer Res. 2008 Jun; 6(6):907-916.
39. Tsuyada A, Chow A, Wu J, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012 Jun 1;72(11):2768-2779. Epub 2012 Apr 3.
40. Witkiewicz AK, Casimiro MC, Dasgupta A, et al. Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy. Cell Cycle. 2009 Jun 1;8(11):1654-1658.
41. Witkiewicz AK, Dasgupta A, Sotgia F, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol. 2009 Jun;174(6):2023-2034. Epub 2009 May 1.
42. Kim M, Koh YJ, Kim KE, et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 2010 Dec 15;70(24):10411-10421. Epub 2010 Nov 5.
43. Cao L, Shao M, Schilder J, et al. Tissue transglutaminase links TGF-b, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012 May 17;31(20): 2521-2534. Epub 2011 Oct 3.
44. van der Horst G, van den Hoogen C, Buijs JT, et al. Targeting of a(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia. 2011 Jun;13(6):516-525.
45. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007 Apr 15; 67(8):3716-3724.
46. Li L, Yoon SO, Fu DD, Zhang X, Choi YS. Novel follicular dendritic cell molecule, 8D6, collaborates with CD44 in supporting lymphomagenesis by a Burkitt lymphoma cell line, L3055. Blood. 2004 Aug 1;104(3):815-821. Epub 2004 Apr 15.
47. Vermeulen L, De Sousa E, Melo F, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010 May;12(5):468-476. Epub 2010 Apr 25.
48. Gilbertson RJ, Gutmann DH. Tumorigenesis in the brain: location, location, location. Cancer Res. 2007 Jun 15;67(12): 5579-5582.
49. Smith BH, Gazda LS, Conn BL, et al. Three-dimensional culture of mouse renal carcinoma cells in agarose macrobeads selects for a subpopulation of cells with cancer stem cell or cancer progenitor properties. Cancer Res. 2011 Feb 1;71(3):716-724. Epub 2011 Jan 24.
50. Basak GW, Srivastava AS, Malhotra R, Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol. 2009 Apr;10(3):345-346.
51. Roodhart JM, Daenen LG, Stigter EC, et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell. 2011 Sep 13;20(3): 370-383.
52. de Jong D, de Boer JP. Predicting transformation in follicular lymphoma. Leuk Lymphoma. 2009 Sep;50(9):1406-1411.
53. Lenz G, Wright G, Dave SS, et al; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in large-Bcell lymphomas. N Engl J Med. 2008 Nov 27;359(22):2313-2323.
54. Arai J, Yasukawa M, Yakushijin Y, Miyazaki T, Fujita S. Stromal cells in lymph nodes attract B-lymphoma cells via production of stromal cell-derived factor-1. Eur J Haematol. 2000 May;64(5): 323-332.
55. Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev. 1998 Apr;162:261-280.
56. Torlakovic E, Torlakovic G, Brunning RD. Follicular pattern of bone marrow involvement by follicular lymphoma. Am J Clin Pathol. 2002 Nov;118(5):780-786.
57. Li L, Choi YS. Follicular dendritic cell-signaling molecules required for proliferation and differentiation of GC-B cells. Semin Immunol. 2002 Aug;14(4):259-266.
58. Li L, Zhang X, Kovacic S, et al. Identification of a human follicular dendritic cell molecule that stimulates germinal center B cell growth. J Exp Med. 2000 Mar 20;191(6):1077-1084.
59. Krautler NJ, Kana V, Kranich J, et al. Follicular dendritic cells emerge from ubiquitous perivascular precursors. Cell. 2012 Jul 6;150(1):194-206.
60. Nakagawa H, Liyanarachchi S, Davuluri RV, et al. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene. 2004 Sep 23;23(44):7366-7377.
61. Kouniavsky G, Khaikin M, Zvibel I, et al. Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. Clin Exp Metastasis. 2002;19(1):55-60.
62. Madlambayan GJ, Butler JM, Hosaka K, et al. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 2009 Nov 5;114(19):4310-4319. Epub 2009 Aug 28.
63. Husson H, Carideo EG, Cardoso AA, et al. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 2001 Dec;115(3):554-562.
64. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005 Aug;23(7):879-894. Epub 2005 May 11.
65. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005 Apr 20; 23(12):2744-2753.
66. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res. 2003 Jul 1;63(13):3833-3839.
67. Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005 Mar 1;11(5):1743-1750.
68. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007 Sep 13;1(3):313-323.
69. Moriyama T, Ohuchida K, Mizumoto K, et al. Enhanced cell migration and invasion of CD133{thorn} pancreatic cancer cells cocultured with pancreatic stromal cells. Cancer. 2010 Jul 15; 116(14):3357-3368.
70. Matsusue R, Kubo H, Hisamori S, et al. Hepatic stellate cells promote liver metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann Surg Oncol. 2009 Sep;16(9):2645-2653. Epub 2009 Jul 9.
71. Dessein AF, Stechly L, Jonckheere N, et al. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res. 2010 Jun 1;70(11):4644-4654. Epub 2010 May 11.
72. Darash-Yahana M, Pikarsky E, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004 Aug;18(11):1240-1242. Epub 2004 Jun 4.
73. Xu Y, Tabe Y, Jin L, et al. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br J Haematol. 2008 Jun;142(2):192-201. Epub 2008 May 19.
74. Rafii A, Mirshahi P, Poupot M, et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS One. 2008;3(12):e3894. Epub 2008 Dec 16.
75. Lis R, Touboul C, Mirshahi P, et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int J Cancer. 2011 Feb 1; 128(3):715-725.
76. Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res. 2011 Oct 1;17(19):6125-6129. Epub 2011 Jun 17.
77. Geoffroy FJ, Allegra CJ, Sinha B, Grem JL. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncol Res. 1994;6(12):581-591.
78. Thomas X, Anglaret B, Magaud JP, Epstein J, Archimbaud E. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk Lymphoma. 1998 Dec;32(1-2):107-119.
79. Shain KH, Landowski TH, Dalton WS. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000 Nov;12(6):557-563.
80. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell. 2010 Aug 27;39(4):493-506.
81. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009 Nov 13;139(4):693-706. Epub 2009 Oct 29.
82. Lin L, Liu A, Peng Z, et al. STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 2011 Dec 1;71(23):7226-7237. Epub 2011 Sep 7.
83. Ginestier C, Liu S, Diebel ME, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010 Feb;120(2):485-497. Epub 2010 Jan 4.
84. Di Stefano AB, Iovino F, Lombardo Y, et al. Survivin is regulated by interleukin-4 in colon cancer stem cells. J Cell Physiol. 2010 Nov;225(2):555-561.
85. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 2007 Oct 11;1(4):389-402.
86. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle. 2008 Feb 1;7(3):309-313. Epub 2007 Nov 30.
87. Yin XL, Wang N, Wei X, et al. Interleukin-12 inhibits the survival of human colon cancer stem cells in vitro and their tumor initiating capacity in mice. Cancer Lett. 2012 Sep 1;322(1):92-97, Epub 2012 Feb 22.
88. Azzi S, Bruno S, Giron-Michel J, et al. Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst. 2011 Dec 21;103(24):1884-1898. Epub 2011 Oct 31.
89. van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res. 2012 Aug;10(8):995-1009. Epub 2012 Jun 19.
90. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005 Sep;5(9): 744-749.
91. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009 Oct 15;114(16):3367-3375. Epub 2009 Jul 27.
92. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer. 2010 Dec 23;10:691.
93. Tan IB, Tan P. Genetics: an 18-gene signature (ColoPrintt) for colon cancer prognosis. Nat Rev Clin Oncol. 2011 Mar;8(3): 131-133. Epub 2011 Feb 8.
94. Saiki Y, Ishimaru S, Mimori K, et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol. 2009 Sep;16(9):2638-2644. Epub 2009 Jun 25.
95. Hostettler L, Zlobec I, Terracciano L, Lugli A. ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients. World J Gastroenterol. 2010 Feb 14; 16(6):732-739.
96. Kawaguchi A, Orba Y, Kimura T, et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood. 2009 Oct 1;114(14):2961-2968. Epub 2009 Aug 5.
97. O'Callaghan K, Lee L, Nguyen N, et al. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood. 2012 Feb 16;119(7):1717-1725. Epub 2011 Dec 20.
98. Zhang C, Cui GH, Liu F, Wu QL, Chen Y. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta Pharmacol Sin. 2006 Nov;27(11):1438-1446.
99. Yang ZJ, Wechsler-Reya RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell. 2007 Jan;11(1):3-5.
100. Huynh AS, Abrahams DF, Torres MS, et al. Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells. PLoS One. 2011;6(5): e20330. Epub 2011 May 27.
101. Yoon SO, Zhang X, Freedman AS, et al. Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol. 2010 Jul;177(1):377-386. Epub 2010 Jun 21.
102. Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):90-100.
103. Tysnes BB. Tumor-initiating and-propagating cells: cells that we would like to identify and control. Neoplasia. 2010 Jul;12(7): 506-515.